TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2025-12-16
王景淵 (王治元)WANG, CHIH-YUAN
- 計畫主持人
- 執行臨床試驗年資 22 年 9 個月
-
ejchung@gmail.com
發表文獻
15筆
11
Wang CY, Wu YL, Sheu WH, Tu ST, Hsu CC, Tai TY. Accountability and utilization of diabetes care from 2005 to 2014 in Taiwan. J Formos Med Assoc. 2019 Nov;118 Suppl 2:S111-S121. doi: 10.1016/j.jfma.2019.08.010. Epub 2019 Oct 4. PMID: 31590971.
12
Wang JS, Chin MC, Chen JF, Huang CN, Hwu CM, Ou HY, Yang YS, Hsu CC, Wang CY. Trends in hospitalizations and emergency department visits among women with hyperglycemia in pregnancy between 2008 and 2017 in Taiwan. Front Endocrinol (Lausanne). 2022 Nov 24;13:1005722. doi: 10.3389/fendo.2022.1005722. PMID: 36506052; PMCID: PMC9730532.
13
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE–TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10. PMID: 30415602.
14
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE–TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10. PMID: 30415602.
15
Wu WC, Peng KY, Lu JY, Chan CK, Wang CY, Tseng FY, Yang WS, Lin YH, Lin PC, Chen TC, Huang KH, Chueh JS, Wu VC. Cortisol-producing adenoma-related somatic mutations in unilateral primary aldosteronism with concurrent autonomous cortisol secretion: their prevalence and clinical characteristics. Eur J Endocrinol. 2022 Sep 14;187(4):519-530. doi: 10.1530/EJE-22-0286. PMID: 35900323.
1
2
